Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients
1Department of Medicine, 2Division of Critical Care Medicine, 3Institute of Health Economics, 4Department of Public Health Sciences, University of Alberta, Edmonton, Alberta, Canada, 5Division of Nephrology, Department of Medicine and 6Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
Correspondence and offprint requests to: Braden Manns, Foothills Medical Centre, 1403, 29th Street NW, Calgary, Alberta T2N 2T9, Canada. Email: braden.manns{at}calgaryhealthregion.ca
 |
Abstract |
|---|
Background. The relative effectiveness and safety of sevelamer for treatment of hyperphosphataemia in dialysis patients is uncertain, as compared with calcium-based phosphate binders.
Methods. We conducted a comprehensive search to identify all randomized cross-over or parallel group studies comparing sevelamer to any other therapy or placebo in adult dialysis patients. Study quality was assessed using the Chalmers Index. Data was extracted and checked using a standardized form and combined using a random effects model.
Results. We identified 14 primary publications of randomized trials (3193 participants) that were eligible for efficacy analysis. In analyses pooling, the 10 studies reporting on serum phosphate and calcium (2501 participants), serum phosphate was significantly lower with calcium-based phosphate binders by 0.12 mmol/l [95% confidence interval (CI) 0.05–0.19], compared with sevelamer. On-treatment calcium–phosphate product was not significantly lower in patients receiving calcium-based phosphate binders (0.12 mmol2/l2, –0.05 to 0.29), compared with sevelamer. Overall mean difference in serum calcium was significantly lower with sevelamer therapy by 0.10 mmol/l (–0.12 to –0.07) and pooled on-treatment decrease in serum bicarbonate was significantly greater with sevelamer therapy by 2.8 mmol/l (2.2 to –3.5). In the five trials which reported all-cause mortality (2429 participants), the overall risk difference for all cause mortality in these five trials was similar between therapies (–2%, 95% CI –6–2). In the three trials which reported serious adverse events (2185 participants), there was a trend towards a lower risk in patients receiving calcium-based phosphate binders (13% lower, 95% CI –2–29).
Conclusions. Compared with calcium-based phosphate binders, use of sevelamer in dialysis patients is associated with similar to slightly higher phosphate levels, similar calcium phosphate product, and slightly lower serum calcium levels. There was no evidence that sevelamer reduced all-cause mortality, cardiovascular mortality, the frequency of symptomatic bone disease or health-related quality of life.
Keywords: calcium; hyperphosphataemia; sevelamer
Received for publication: 7. 3.07
Accepted in revised form: 5. 6.07
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in NDT:
- Sevelamer: a promising but unproven drug
- Suetonia C. Palmer, Jonathan C. Craig, and Giovanni F. M. Strippoli
NDT 2007 22: 2742-2745.[Extract] [FREE Full Text] - Economic evaluation of sevelamer in patients with end-stage renal disease
- Braden Manns, Scott Klarenbach, Helen Lee, Bruce Culleton, Fiona Shrive, and Marcello Tonelli
NDT 2007 22: 2867-2878.[Abstract] [FREE Full Text] - In this issue ...
NDT 2007 22: i.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  S. A. Jamal, D. Fitchett, C. E. Lok, D. C. Mendelssohn, and R. T. Tsuyuki The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis Nephrol. Dial. Transplant., October 1, 2009; 24(10): 3168 - 3174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Johnson Sevelamer versus calcium-based phosphate binders in chronic kidney disease: what should we conclude from the evidence to date? Nephrol. Dial. Transplant., October 1, 2009; 24(10): 2970 - 2972. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Saliba and B. El-Haddad Secondary Hyperparathyroidism: Pathophysiology and Treatment J Am Board Fam Med, September 1, 2009; 22(5): 574 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Palmer, J. C. Craig, and G. F. M. Strippoli Taking aim at targets Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1358 - 1361. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Baer, N. Lameire, and W. Van Biesen Late referral of patients with end-stage renal disease: an in-depth review and suggestions for further actions NDT Plus, April 29, 2009; (2009) sfp050v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Savica, P. Monardo, D. Santoro, A. Mallamace, and G. Bellinghieri Time-dependent effect of sevelamerHCl on the cardiovascular system Nephrol. Dial. Transplant., June 1, 2008; 23(6): 2102 - 2103. [Full Text] [PDF]
|
|
|
|
|
|
O. Wrong and C. Harland Sevelamer Nephrol. Dial. Transplant., June 1, 2008; 23(6): 2108 - 2108. [Full Text] [PDF]
|
|
|
|
|
|
S. Palmer and G. Strippoli Reply Nephrol. Dial. Transplant., June 1, 2008; 23(6): 2101 - 2102. [Full Text] [PDF]
|
|
|
|
|
|
S. Palmer and G. Strippoli Reply: Vitamin D compounds in chronic kidney disease: change may be needed for good! Nephrol. Dial. Transplant., June 1, 2008; 23(6): 1789 - 1792. [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Kovesdy, R. Mehrotra, and K. Kalantar-Zadeh Battleground: Chronic Kidney Disorders Mineral and Bone Disease Calcium Obsession, Vitamin D, and Binder Confusion Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 168 - 173. [Abstract] [Full Text] [PDF]
|
|